Liquidia is exploding higher following the announcement on the afternoon of October 13 that the company reached a global settlement with United Therapeutics to resolve all pending patent litigation. This agreement ensures the continued commercialization of the lung disease drug YUTREPIA and is being characterized by market observers as a better-than-expected outcome for the company. While the stock had previously faced significant volatility, including a securities investigation notice regarding a prior 57% loss, this $380.7 million settlement has effectively removed the legal overhang that had weighed on the share price.